SA
TEVA icon

SpiderRock Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

SpiderRock Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Hold
0
– -$15K – 1169
2017
Q1 		– Hold
0
– – – 719

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SpiderRock Advisors's TEVA Position: Q3 2024 in Review

SpiderRock Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 7.7% in Q3 2024, selling an estimated $154K and leaving 105,140 shares worth $1.89M. The position accounts for 0.03% of the portfolio, ranked #335.

SpiderRock Advisors first reported a position in TEVA in Q1 2024 and has held it in 3 quarters since. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • SpiderRock Advisors held 105,140 shares of Teva Pharmaceuticals worth $1.89M as of Q3 2024.
  • SpiderRock Advisors sold 8,782 Teva Pharmaceuticals shares in Q3 2024, an estimated $154K.
  • Teva Pharmaceuticals made up 0.03% of SpiderRock Advisors's portfolio in Q3 2024, its #335 holding.
  • SpiderRock Advisors first reported a position in Teva Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 543 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.